- 米国企業
- Anika Therapeutics, Inc.
Anika Therapeutics, Inc.ANIK
| 2011年 12月31日 | 2012年 12月31日 | 2013年 12月31日 | 2014年 12月31日 | 2015年 12月31日 | 2016年 12月31日 | 2017年 12月31日 | 2018年 12月31日 | 2019年 12月31日 | 2020年 12月31日 | 2021年 12月31日 | 2022年 12月31日 |
---|
Cash and cash equivalents | 36 | 44 | 63 | 100 | 111 | 104 | 133 | 89 | 157 | 96 | 94 | 86 |
---|
Accounts receivable, net | - | - | - | 7 | 28 | 21 | 24 | 70 | 27 | 3 | - | 35 |
---|
Inventories | 7 | 8 | 11 | 12 | 15 | 16 | 22 | 21 | 22 | 46 | 36 | 40 |
---|
Prepaid expenses and other current assets | 2 | 2 | 865,957 | 959,305 | 1 | 2 | 3 | 2 | 4 | 9 | 8 | 9 |
---|
Total current assets | 64 | 77 | 95 | 139 | 176 | 170 | 206 | 203 | 234 | 177 | 169 | 170 |
---|
Property and equipment, net | 36 | 35 | 33 | 32 | 40 | 52 | 56 | 54 | 51 | 51 | 48 | 48 |
---|
Right-of-use assets | - | - | - | - | - | - | - | - | 23 | 23 | 21 | 31 |
---|
Other long-term assets | - | - | - | - | - | - | 1 | 5 | 7 | 15 | 20 | 17 |
---|
Deferred tax assets | - | - | - | - | - | - | - | - | - | - | - | 1 |
---|
Intangible assets, net | 23 | 20 | 19 | 15 | 12 | 10 | 11 | 9 | 8 | 91 | 82 | 75 |
---|
Goodwill | 9 | 9 | 9 | 8 | 7 | 7 | 8 | 8 | 8 | 8 | 8 | 7 |
---|
Total assets | 133 | 142 | 156 | 194 | 236 | 240 | 283 | 279 | 331 | 366 | 348 | 349 |
---|
Accounts payable | 4 | 2 | 3 | 1 | 8 | 2 | 7 | 3 | 4 | 9 | 8 | 9 |
---|
Accrued expenses and other current liabilities | - | - | - | - | 5 | 6 | 6 | 8 | 12 | 15 | 18 | 19 |
---|
Contingent consideration | - | - | - | - | - | - | - | - | - | 13 | 4 | - |
---|
Total current liabilities | 15 | 14 | 9 | 6 | 17 | 9 | 13 | 11 | 16 | 37 | 30 | 28 |
---|
Other long-term liabilities | 2 | 2 | 1 | 893,935 | 781,000 | 2 | 1 | 1 | 0 | 1 | 1 | 0 |
---|
Deferred tax liability | - | - | - | - | - | - | - | - | 4 | 12 | 10 | 6 |
---|
Lease liabilities | - | - | - | - | - | - | - | - | 21 | 21 | 19 | 29 |
---|
Preferred stock, $0.01 par value; 1,250 shares authorized, no shares issued and outstanding at December 31, 2022 and 2021, respectively | - | - | - | - | - | - | - | - | - | - | - | - |
---|
Common stock, $.01 par value; 90,000 shares authorized, 14,625 and 14,441 shares issued and outstanding at December 31, 2022 and 2021, respectively | 136,305 | 138,659 | 142,893 | 148,517 | 150,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
---|
Additional paid-in-capital | - | - | 71 | 78 | 82 | 62 | 69 | 51 | 49 | 55 | 67 | 81 |
---|
Accumulated other comprehensive loss | - | - | - | - | -6,649,000 | -7 | -5 | -6 | -6 | -5 | -6 | -6 |
---|
Retained earnings | 34 | 46 | 67 | 105 | 136 | 168 | 200 | 218 | 245 | 221 | 226 | 211 |
---|
Total stockholders’ equity | 95 | 109 | 136 | 178 | 211 | 223 | 263 | 264 | 288 | 272 | 287 | 286 |
---|
Total liabilities and stockholders’ equity | 133 | 142 | 156 | 194 | 236 | 240 | 283 | 279 | 331 | 366 | 348 | 349 |
---|